PreveCeutical Medical says Sol-gel cannabinoid program a success as it eyes development and commercialization

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) announced Monday the successful completion of its cannabinoid Sol-gel program with the University of Queensland and UniQuest Pty Ltd.

The company said the final report on the program confirmed the successful chemical profiling of the solvent-derived cannabinoid extracts from cannabis plants, providing the company with valuable information for formulation development using cannabinoid Sol-gels. 

PreveCeutical said the information will enable it to control the quality of batch-to-batch variations in plant extract chemistries and provide optimization of Sol-gel formulation strategies. 

READ: PreveCeutical Medical successfully concludes Sol-gel cannabinoid delivery program

The Vancouver-based company said it will now be able to develop and commercialize different combinations of the cannabinoid extracts infused into Sol-gel formulations to treat different ailments. 

PreveCeutical said its objectives are to develop, commercialize, and seek other third party clinical-proven formulations to be infused with the sol-gel delivery platform.

The cannabinoid Sol-gel program for nose-to-brain delivery has been developed to be water-soluble without alcohol or solvent content, the company noted.

“We are excited with the research findings and successful in-vitro results from the cannabinoid Sol-gel program,” PreveCeutical CEO Stephen Van Deventer said in a statement. “This will potentially create several therapeutic applications in managing controlled delivery of cannabinoidal combinations in clinical study settings, that would be of great value”.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Story by ProactiveInvestors